ArticleJournal of traditional and complementary medicine2026
Inhibitory effect of standardized
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia is a muscle disease typically characterized by an age-related loss of muscle mass and function, leading to the deterioration of health in older adults. The current study aimed to investigate the therapeutic potential of standardized Methods: To assess the inhibitory effects of KPE on sarcopenia, 18-month-old C57BL/6J mice were employed as an aged model. The mice were orally administered 100 and 200 mg/kg KPE daily for 8 weeks. Results: KPE improved age-reduced grip strength and exercise endurance. It not only increased hindlimb muscle weight, volume, and myofiber cross-sectional area but also decreased abdominal fat volume and adipose tissue weight. KPE downregulated the mRNA expression of tumor necrosis factor alpha and interleukin-6 by inactivating nuclear factor kappa B protein expression and increasing the mRNA expression of anti-oxidant enzymes. Moreover, it significantly reduced the mRNA expression of muscle ring finger-1 and muscle atrophy F-box for proteolysis and stimulated the mammalian target of rapamycin pathway for protein translation by stimulating the phosphatidylinositol 3-kinase/Akt pathway. KPE also increased the relative mitochondrial DNA content by upregulating peroxisome proliferator-activated receptor gamma coactivator 1 alpha, nuclear respiratory factor 1, and mitochondrial transcription factor A mRNA expression. Conclusion: This study's findings demonstrate that KPE improves age-induced sarcopenia by regulating protein turnover and mitochondrial homeostasis. Therefore, KPE is potentially useful as a functional ingredient that inhibits or decelerates sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.